First Assessment of Oral Iron Chelator HBED Increases Iron Excretion in Black Rhinoceros (Diceros bicornis minor)

Black rhinoceros (<i>Diceros bicornis</i>) face threats to survival due to poaching in the wild and an incomplete understanding of preventive health monitoring under human care. Black rhinos under human care develop iron overload disorder (IOD) which is associated with predisposition to other disease, compromised immune function, hemolytic crisis, and death. Management of IOD is challenging but has been mitigated in some cases with dietary intervention and phlebotomy and documented through serum biomarker evaluation. Chelation therapy to reduce iron is rare in rhinos partially because of limited product availability and route of administration. An iron-specific chelator HBED (N,N'-Di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid) was investigated for oral use in southern black rhinos (<i>n</i> = 3) after successful testing was performed with equids as a model. Using a cross-over design, we tested the efficacy of short-term HBED administration. HBED was dosed at 40 mg/kg body weight for 10 days and resulted in increased urinary excretion of iron but unaltered fecal iron excretion in rhinos compared to control trials. Two rhinos maintained blood chemistry and cell distribution considered normal for the species. The third rhino experienced a hemolytic event after stopping HBED administration in the same time frame and at the same dose as the two conspecifics but fully recovered. Careful monitoring and tapering the drug at the completion of treatment is warranted, especially if the rhino's iron load is considered high. HBED's potential to induce iron excretion safely, as well as prevent excessive dietary iron uptake, may significantly benefit the black rhino population under human care.